Niox Group PLC Return of Capital by way of special Dividend (8763B)
07 6월 2023 - 3:00PM
UK Regulatory
TIDMNIOX
RNS Number : 8763B
Niox Group PLC
07 June 2023
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("UK MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of UK MAR. The
persons taking responsibility for this announcement are the Company
contacts named below.
NIOX GROUP PLC
("NIOX" or the "Company" and, together with its subsidiaries,
the "Group")
Return of Capital by way of Special Dividend
Further to the announcement on 18 May 2023 that the Board
believes that the cash generation and resources of the Group are
now at a level where it is appropriate to commence the payment of a
dividend, the Company is pleased to announce that a special
dividend of 2.5p per ordinary share will be paid on 15 September
2023 to shareholders on the register as at Friday 18 August 2023.
The associated ex-dividend date will be Thursday 17 August
2023.
Ian Johnson, NIOX's Executive Chairman, said: " I am pleased
that the operating income we are now generating has enabled us to
fund a special dividend in addition to meeting the ongoing
operating needs of the business. We remain confident in the
prospects for the business and now anticipate paying further
dividends to shareholders from our ongoing cash flow. "
Contacts
NIOX
Ian Johnson, Executive Chairman Tel: +44 (0) 1865 405 560
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Aubrey Powell/ Jen Boorer Tel: +44 (0) 20 7496 3000
About NIOX
Our mission is to improve asthma diagnosis and management by
greater patient access to FeNO testing. Asthma is one of the
biggest healthcare issues globally with 340 million sufferers, many
of whom are undiagnosed or are misdiagnosed. The Group is engaged
in the design, development, and commercialisation of medical
devices for the measurement of FeNO, a precise biomarker for
asthma. Our market leading device, NIOX VERO(R), is increasingly
recognised by healthcare professionals as an important tool to
improve the diagnosis and management of asthma. NIOX VERO(R) is
also the device of choice by leading clinical research
organisations for respiratory studies.
NIOX provides products and services via its direct sales
organisation and extensive distributor network in 50 countries. For
more information, please visit www.niox.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUUPQUPWPPQ
(END) Dow Jones Newswires
June 07, 2023 02:00 ET (06:00 GMT)
Niox (LSE:NIOX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Niox (LSE:NIOX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024